Illumina

Illumina logo

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Illumina has filed a new lawsuit against Premaitha, claiming it infringes on an Illumina patent related to noninvasive prenatal testing.

Reporting on aneuploidies across all chromosomes could improve the accuracy of some NIPTs and provide information about miscarriage risk and other complications.

The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.

NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.

The Korean molecular diagnostics startup is planning to launch the new offering in Europe, as well as China and other Southeast Asian countries.

Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.

The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."

Since April 1, noninvasive prenatal testing, provided by three university genetic centers, is available to all pregnant women in the Netherlands for €175 as part of the TRIDENT-2 study.

The firm can now sell VeriSeq NIPT as a CE-IVD in Europe for trisomies 21, 18, and 13, as well as some sex chromosomal aneuploidies. 

The arrangement will allow Illumina to market and promote Kailos' research solutions for pharmacogenetic target enrichment.

Pages